RxDoctor Payments Data

Catherine Crosby, APRN

Psychiatric/Mental Health · Summerville, SCNPI 1316308794

Payments from drug & device makers

$2,448in general payments, 2019–2025

Across 46 payments — averaging $53.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$419
  • AbbVie$329
  • Johnson & Johnson$236
  • Eisai Inc.$145
  • GSK$142
  • Novo Nordisk$134
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$2,448100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,448 in reported general payments places this provider in the 80th percentile of 354 psychiatric/mental health providers in South Carolina.

See all psychiatric/mental health providers in South Carolina

Medicare billing

Part B allowed, 2024
$395,531
Medicare patients
201
Services billed
5,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$29,799
EliquisApixaban31$26,756
XareltoRivaroxaban13$12,724
FarxigaDapagliflozin Propanediol12$11,003
MyrbetriqMirabegron13$6,557
Atorvastatin Calcium143$2,066
Lidocaine18$1,716
Memantine Hcl33$1,500
Diclofenac Sodium19$1,455
Gabapentin58$1,444
Bupropion XlBupropion Hcl15$1,427
Tramadol Hcl71$1,276
Potassium Chloride57$1,246
Duloxetine Hcl37$1,217
Albuterol Sulfate HfaAlbuterol Sulfate41$1,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$134$29,79922 claims
Johnson & JohnsonXarelto$236$12,72413 claims
AstraZenecaFarxiga$15$11,00312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 354 psychiatric/mental health providers in South Carolina.

Other psychiatric/mental health in Summerville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →